A detailed history of Orbimed Advisors LLC transactions in Scholar Rock Holding Corp stock. As of the latest transaction made, Orbimed Advisors LLC holds 742,300 shares of SRRK stock, worth $32.6 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares
742,300
Previous 1,074,382 30.91%
Holding current value
$32.6 Million
Previous $8.95 Million 33.57%
% of portfolio
0.14%
Previous 0.22%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$7.63 - $9.71 $2.53 Million - $3.22 Million
-332,082 Reduced 30.91%
742,300 $5.95 Million
Q2 2024

Aug 14, 2024

SELL
$7.84 - $16.79 $19.6 Million - $42 Million
-2,500,250 Reduced 69.94%
1,074,382 $8.95 Million
Q1 2024

May 15, 2024

SELL
$13.2 - $17.76 $8.85 Million - $11.9 Million
-670,368 Reduced 15.79%
3,574,632 $63.5 Million
Q4 2023

Feb 14, 2024

BUY
$6.52 - $20.32 $14.4 Million - $44.9 Million
2,211,211 Added 108.72%
4,245,000 $79.8 Million
Q3 2023

Nov 14, 2023

BUY
$6.02 - $7.76 $7.81 Million - $10.1 Million
1,298,144 Added 176.46%
2,033,789 $14.4 Million
Q2 2023

Aug 14, 2023

BUY
$5.79 - $9.11 $1.28 Million - $2.01 Million
220,645 Added 42.84%
735,645 $5.55 Million
Q1 2023

May 15, 2023

SELL
$7.36 - $12.72 $2.68 Million - $4.63 Million
-364,003 Reduced 41.41%
515,000 $4.12 Million
Q4 2022

Feb 14, 2023

BUY
$7.02 - $9.76 $1.48 Million - $2.06 Million
211,060 Added 31.6%
879,003 $7.95 Million
Q3 2022

Nov 14, 2022

SELL
$5.33 - $11.3 $2.18 Million - $4.62 Million
-408,597 Reduced 37.95%
667,943 $4.63 Million
Q2 2022

Aug 15, 2022

BUY
$4.66 - $13.96 $5.02 Million - $15 Million
1,076,540 New
1,076,540 $5.91 Million

Others Institutions Holding SRRK

About Scholar Rock Holding Corp


  • Ticker SRRK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,640,600
  • Market Cap $2.27B
  • Description
  • Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...
More about SRRK
Track This Portfolio

Track Orbimed Advisors LLC Portfolio

Follow Orbimed Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.